^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Fruzaqla (fruquintinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
Published date:
11/08/2023
Excerpt:
Takeda...announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy...
Source:
Published date:
11/08/2023
Excerpt:
FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.
Source:
Title:
Chi-Med Announces the Approval of Fruquintinib Capsules for Previously Treated Colorectal Cancer in China
Published date:
09/05/2018
Excerpt:
Hutchison China MediTech Limited...today announces that fruquintinib capsules have been granted approval for drug registration by the National Medical Products Administration of China...for the treatment of metastatic colorectal cancer...
Source:
Title:
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
Published date:
06/15/2023
Excerpt:
Median overall survival was 7·4 months (95% CI 6·7–8·2) in the fruquintinib group versus 4·8 months (4·0–5·8) in the placebo group (hazard ratio 0·66, 95% CI 0·55–0·80; p<0·0001)….Fruquintinib treatment resulted in a significant and clinically meaningful benefit in overall survival compared with placebo in patients with refractory metastatic colorectal cancer.
DOI:
https://doi.org/10.1016/S0140-6736(23)00772-9
Trial ID:
Source:
Title:
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
Published date:
05/25/2023
Excerpt:
Takeda...announced that the U.S. Food and Drug Administration (FDA) has granted priority review of the New Drug Application (NDA) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).
Source:
Title:
Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.
Published date:
01/17/2023
Excerpt:
691 pts were randomized (F: 461 vs P: 230) and 686 pts received study drug (F: 456 vs P: 230). Median treatment Cycles received (range) were 3 (1, 20) for F vs 2 (1, 13) for P...These results, along with improved OS and PFS and favorable toxicity profile, further support F as a potential new treatment option for patients with refractory mCRC.
DOI:
10.1200/JCO.2023.41.3_suppl.67
Trial ID:
Source:
Title:
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
Published date:
06/26/2018
Excerpt:
Among Chinese patients with metastatic CRC who had tumor progression following at least 2 prior chemotherapy regimens, oral fruquintinib compared with placebo resulted in a statistically significant increase in overall survival.
DOI:
10.1001/jama.2018.7855
Trial ID:
